FDA recall: a glaucoma eye drop where the cap spike breaks and no drop can be delivered — the reason is the container, not the medicine (Micro Labs)
A combination eye drop of dorzolamide hydrochloride and timolol maleate was recalled as a defective container after the firm received multiple complaints of broken cap spikes and undeliverable drops. It is distributed nationwide.
Recall overview (primary data)
- ClassificationClass II
- Product typeDrug
- Recalling firmMICRO LABS USA INC
- ReasonDefective Container: Firm received multiple complaints of broken cap spikes and undeliverable drops.
- DistributionNationwide in the USA.
- Recall initiated2026-07-22
Key points
- A dorzolamide and timolol combination eye drop was recalled as a defective container after multiple complaints of broken cap spikes and undeliverable drops.
- Many eye drops use a spike inside the cap to pierce the bottle; once broken, nothing comes out however sound the contents.
- Manufactured by Micro Labs Limited in India and distributed by Micro Labs USA, with nationwide distribution.
- Eye drops that lower intraocular pressure are designed for daily use, so one unusable bottle means dosing lapses until a replacement arrives.
- Of the 1,408 records this site holds as of 2026-08-31, 10 touch on a defective container or cap, against 37 for foreign matter or precipitate and 36 for subpotency.
1The medicine is right but does not reach
What this record cites is neither an ingredient problem nor contamination. A spike on the container cap breaks, and the solution cannot be dispensed. Many eye drops use a spike inside the cap to pierce the bottle, and once that breaks not a single drop comes out however sound the contents. Quality tends to be measured by what is inside a product, yet whether it can be used is settled by the container as well. It is also the kind of fault that first becomes apparent immediately before use.
2The context of glaucoma treatment
The product combines two ingredients that lower intraocular pressure. Medicines of this kind are designed to hold their effect by being used at set times every day. If one bottle cannot be used, dosing lapses until a replacement arrives. Because it is a prescription product, obtaining another from a pharmacy takes procedure and time.
A treatment can be interrupted while the contents remain intact, which is how a container defect differs in effect from a problem with the ingredient.
3Container defects appear in 10 of 1,408 records
Sorting the 1,408 FDA recall records this site holds as of 2026-08-31 by the wording of their reasons, 10 touch on a defective container or cap. That is fewer than the 37 citing foreign matter or precipitate and the 36 citing subpotency. Drug recalls centre on specifications for what is inside, and the container is rarely the reason. What deserves note is that this record begins from complaints received by the firm.
Deviations in the contents can be caught by pre-shipment testing, whereas being unable to open something first appears in the hands of the person using it.
Why it matters
Product quality is discussed in terms of specifications for the contents, but to a user the container is part of the same product. Faults in the parts involved in opening or dispensing are hard to catch in pre-shipment testing and surface only once complaints arrive. For medicines used continuously, one unusable unit connecting directly to an interruption in treatment also belongs in the estimate of impact.
FAQ
Is there a problem with the medicine itself?
Why is it found through complaints?
What happens if dosing lapses?
Sources (primary)
Source: openFDA (U.S. FDA, CC0 public domain). Data is provided as-is and must not be used for medical decisions. Verify the latest and exact details with the official FDA recall information. This site is not endorsed or certified by the U.S. FDA.
- FDA recall information (official)
- openFDA (data provider)
- Recall number: D-0730-2026